What regimen would you recommend for a younger, fit, transplant eligible patient with relapsed IDH1 positive AML?

If there was only one answer! The decision revolves around co-occurring cyto and molecular genetic abnormalities (in addition to IDH1) and the duration of remission in first CR. In general, IDH mutant AML - without other high-risk genetic lesions - is very responsive to all of our treatments whether it's reinduction chemotherapy or aza/ven. If the goal of therapy is to get the patient into an MRD negative CR and proceed to a transplant (and they have been in CR for over 6 months without other high-risk genetic abnormalities), I have a frank discussion about the options. I believe the current standard of care in a patient like this remains reinduction type chemotherapy (FLAG-IDA, MEC, etc) but I also offer the possibility of aza/ven as a fir...